文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 基础医学 > EMT, cancer stem cells and drug resistance an emerging axis of
侵权投诉

EMT, cancer stem cells and drug resistance an emerging axis of

NIH Public Access Author Manuscript Oncogene. Author manuscript; available in PMC 2011 September 20. Published in final edited form as: Oncogene. 2010 August 26; 29(34): 4741–4751. doi:10.1038/onc.2010.215.

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer Anurag Singh1 and Jeffrey Settleman1 1Massachusetts General Hospital Cancer Center and Harvard Medical School, 149 13thStreet, Charlestown, MA 02129, USA

Abstract Tumors are cellularly and moleculary heterogeneous, with subsets of undifferentiated cancer cells exhibiting stem cell-like features (CSCs). Epithelial to mesenchymal transitions (EMT) are transdifferentiation programs that are required for tissue morphogenesis during embryonic development. The EMT process can be regulated by a diverse array of cytokines and growth factors, such as TGF-β whose activities are dysregulated during malignant tumor progression. Thus, EMT induction in cancer cells results in the acquisition of invasive and metastatic properties. Recent reports indicate that the emergence of CSCs occurs in part as a result of EMT, for example, via cues from tumor stromal components. Recent evidence now indicates that EMT of tumor cells not only causes increased metastasis but also contributes to drug resistance. In this review, we will provide potential mechanistic explanations for the association between EMT induction and the emergence of CSCs. We will also highlight recent studies implicating the function of TGF-β regulated non-coding RNAs in driving EMT and promoting CSC self-renewal. Finally we will discuss how EMT and CSCs may contribute to drug resistance as well as therapeutic strategies to overcome this clinically.

Introduction Cellular heterogeneity is a histological hallmark of many cancers (Pardal et al., 2003). Despite their clonal origin, tumors are comprised of cells with varied morphological and molecular features. Rare tumor-initiating cells with stem cell-like properties in both hematopoietic and solid malignancies have been identified and classified using distinct cell surface markers. These cancer stem cells (CSCs) can self-renew and differentiate to generate the cellular heterogeneity of the originating tumor (Al-Hajj et al., 2003; Hermann et al., 2007; Lapidot et al., 1994; O’Brien et al., 2007; Ricci-Vitiani et al., 2007; Singh et al., 2004). However, whether CSCs are truly the only cells with de facto tumorigenic potential remains controversial (Gupta et al., 2009a; Quintana et al., 2008). Regardless, tumors are clearly histologically heterogenous, with subsets of cancer cells exhibiting distinct molecular profiles (Gupta et al., 2009a). Furthermore, cells with different molecular characteristics within the same tumor respond differently to anti-cancer therapeutics, leading to drug resistance (Zhou et al., 2009). Cancer cells may also undergo adaptive changes following therapy, e

xacerbating drug resistance. In epithelial cancers, these adaptive changes may involve, at least in part, epithelial to mesenchymal transitions (EMT) and the reverse process (MET). These are developmental programs that can be usurped by oncogenically transformed cells during tumor progression (Thiery et al., 2009).

Correspondence to: Jeffrey Settleman.

EMT, cancer stem cells and drug resistance an emerging axis of

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email